The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Lisa Kochen
No Relationships to Disclose
 
Doerthe Vortmeyer
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Immutep; Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Lilly; MacroGenics; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Immutep; Ipsen; Lilly; Medac; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Timorshah Habibzada
No Relationships to Disclose
 
Marius Brunner
No Relationships to Disclose
 
Thomas Jens Ettrich
Consulting or Advisory Role - AstraZeneca; Bayer; BMS GmbH & Co. KG; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Eisai; Incyte; Ipsen; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen
 
Maria A Gonzalez-Carmona
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Lilly O.; Roche
Research Funding - Eisai
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly O.
 
Claus-Henning Kohne
Honoraria - Amgen; Bristol-Myers Squibb; Pierre Fabre
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Pierre Fabre
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; Lilly O.; MSD; Roche
 
Dominik Paul Modest
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Cor2Ed; Incyte; IQvia; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Roche; SERVIER
Research Funding - Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER